ORMP

Oramed Pharmaceuticals Inc. (ORMP) - Q2 2024 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended June 30, 2024. Oramed Pharmaceuticals Inc. is a biotechnology company focused on oral drug delivery technology, primarily for insulin and vaccines. Following the termination of its Phase 3 oral insulin trials in early 2023, the Company is currently conducting a strategic review and has significantly reduced R&D activities. A key development in the period was the entry into a Joint Venture (JV) agreement with Hefei Tianhui Biotech Co., Ltd. (HTIT) to develop and commercialize oral insulin products.

Key Financial Metrics

Material Changes vs. Prior Period

• Profitability Shift: The Company reported a Net Income of $10.74 million for the six months ended June 30, 2024, compared to a Net Loss of $4.92 million in the same period in 2023. This reversal is primarily driven by a $19.32 million gain in "Financial Income, Net," largely due to the revaluation of investments in Scilex Holding Company.
• Expense Reduction: Research and Development (R&D) expenses decreased by 58% to $2.62 million (six months 2024) from $6.25 million (six months 2023), reflecting the termination of Phase 3 trials. Sales and Marketing expenses dropped to $0 from $0.38 million in the prior year.
• Liquidity Improvement: Cash and cash equivalents increased significantly to $84.75 million from $9.06 million at year-end 2023. This was driven by proceeds from short-term deposits and long-term investments, offset by the repayment of $49.55 million in short-term borrowings.
• Debt Elimination: The Company fully repaid its short-term borrowings of approximately $51 million during the period, reducing current liabilities from $53.21 million to $3.73 million.

Guidance, Outlook, and Risks

• Joint Venture: The Company signed a JV agreement with HTIT Biotech. HTIT will contribute $70 million in cash, while Oramed contributes $20 million (cash and stock) plus IP. The JV aims to initiate a new Phase 3 oral insulin trial in the U.S. using a protocol recently submitted to the FDA. Consummation is contingent on additional agreements.
• Strategic Review: Management is evaluating potential strategic opportunities to enhance shareholder value. R&D activities remain reduced during this review.
• Stock Buyback: In June 2024, the Board authorized a $20 million stock buyback program. Subsequent to the quarter end, the Company repurchased 118,522 shares for approximately $277,000.
• Scilex Transaction: The Company holds a Senior Secured Promissory Note and warrants from Scilex. As of June 30, 2024, Scilex had repaid $40 million of the Note. The fair value of these assets is subject to volatility based on Scilex's stock price and repayment ability.
• Risks: Key risks include the uncertainty of the JV consummation, the ability to recover proceeds from Scilex, the outcome of future clinical trials, and geopolitical risks related to operations in Israel.

Investor Verification Checklist

• Scilex Asset Valuation: Verify the fair value assumptions and credit risk associated with the $66.2 million Note and warrants held from Scilex, which drove the majority of the period's net income.
• JV Consummation: Monitor the status of the additional agreements required to finalize the Joint Venture with HTIT Biotech.
• Cash Burn Rate: Confirm the sustainability of the current reduced burn rate and the timeline for the new Phase 3 trial initiation.
• Tax Provision: Review the $1.63 million tax expense recognized, which is attributable to the anticipated taxable income from the Scilex transaction and the utilization of tax loss carryforwards.
• Buyback Execution: Track the execution of the $20 million share repurchase program authorized in June 2024.